Navigation Links
Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
Date:9/10/2012

THOUSAND OAKS, Calif., Sept. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Ray Jordan to the new position of senior vice president, Corporate Affairs, effective October 1.

Jordan will report directly to Robert A. Bradway, president and chief executive officer, and will be responsible for strategic communications across Amgen, including internal and external communications, issues management and philanthropy.

Since 2003 Jordan has served as communications leader at Johnson & Johnson, responsible for corporate communications and public affairs for more than 250 operating companies in 60 countries.  Prior to joining Johnson & Johnson, Jordan was vice president, communications and information, for Pfizer, where he held a range of positions over the course of 17 years. He also served as chair of PhRMA's public affairs section and of the National Pharmaceutical Council's User Group. Earlier in his career, Jordan was a reporter for a regional daily newspaper and held positions with Bristol-Myers and Dun & Bradstreet.

"We are very pleased to have Ray join Amgen," said Bradway.  "He is a strategic thinker and communicator with skills honed at two respected global health care companies.  Ray's background in both business management and communication will serve Amgen well as we execute on our strategy to deliver results for both patients and shareholders."

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
David Caouette, 805-447-2661 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
11. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... Austin, TX May 24, 2017 (PRWEB) , ... ... ... Require Constant Connectivity , Medical systems are increasingly being developed with Wi-Fi connectivity ... to be easily moved from room to room. In addition, compact mobile devices ...
(Date:5/23/2017)... , ... May 23, 2017 ... ... an unlimited source of human cardiovascular cells for research and the development ... makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to ...
(Date:5/23/2017)... ... 23, 2017 , ... Vortex Biosciences , provider of circulating tumor cell ... tumor cells using Vortex microfluidic technology ” in Nature Precision Oncology on May 8th. ... Di Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The ...
(Date:5/23/2017)... ... , ... Cambridge Semantics , the leading provider of Big Data management ... and Expo in Boston May 23-25 with a featured speaker and solution demos ... Lake is also a finalist for the Best of Show award. , James LaPointe, ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):